


CLAIMS

What is claimed is:

1. A compound of Formula (I):




Formula (I);

wherein:

R^1 is $-C(O)OR^{15}$ or $-C(O)NR^{10}R^{11}$;

R^2 is H, halogen, C_{1-6} alkyl, or C_{1-6} haloalkyl;



A is N or C(H);

X is $-O-$, $-N(R^{16})-$, or $-CH_2N(R^{16})CH_2-$;

Y is $-CH_2-$ or $-C(O)-$;

Z is $-S-$, $-O-$, or $-N(R^{18})-$;

R^4 is H, halogen, $-OR^7$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, $-C(O)NR^8R^9$, C_{3-8} cycloalkyl, C_{2-9} heterocycloalkyl, $-C_{1-6}$ alkyl- C_{2-9} heterocycloalkyl, C_{6-10} aryl, or C_{1-9} heteroaryl, wherein C_{3-8} cycloalkyl, C_{2-9} heterocycloalkyl, $-C_{1-6}$ alkyl- C_{2-9} heterocycloalkyl, C_{6-10} aryl, or C_{1-9} heteroaryl are optionally substituted with 1 or 2 R^{14} ;

R^5 is H, halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, or phenyl;

R^6 is H, halogen or C_{1-6} alkyl;

R^7 is H, C_{1-6} alkyl, C_{1-6} haloalkyl, $-C_{1-6}$ alkyl-OH, C_{2-9} heterocycloalkyl, C_{6-10} aryl, or C_{1-9} heteroaryl, wherein C_{2-9} heterocycloalkyl, C_{6-10} aryl, or C_{1-9} heteroaryl are optionally substituted with 1 or 2 R^{14} ;

each R^8 and each R^9 are independently selected from H and C_{1-6} alkyl; or R^8 and R^9 together with the nitrogen to which they are attached are combined to form a heterocycloalkyl ring;

R^{10} and R^{11} are each independently H or C_{1-6} alkyl;

R^{12} is H, halogen, or C_{1-6} alkyl;

R^{13} is H or C_{1-6} alkyl;

each R^{14} is independently selected from halogen, -OH, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, $-C_{1-6}$ alkyl-OH, C_{3-8} cycloalkyl, $-C(O)OH$, $-C(O)NR^8R^9$, $-SO_2-C_{1-6}$ alkyl, and $-N(R^{17})C(O)-C_{1-6}$ alkyl;

R^{15} is H or C_{1-6} alkyl;

R^{16} is H, C_{1-6} alkyl, $-C(O)-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl-OH, or $-CH_2CO_2H$;

R^{17} is H or C_{1-6} alkyl;

R^{18} is H or C_{1-6} alkyl;

v is 0 or 1;

n is 0 or 1;


m is 0 or 1;

p is 0, 1, or 2; and

q is 0, 1 or 2;

or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.

2. The compound of claim 1, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or



pharmaceutically acceptable salt thereof, wherein R^3 is


3. The compound of claim 2, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein m is 1, n is 1, q is 0, and p is 2.

4. The compound of any one of claims 2-3, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein Y is $-CH_2-$.


5. The compound of any one of claims 1-4, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R^{13} is H and R^{12} is H.


6. The compound of any one of claims 2-5, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein A is C(H).


7. The compound of any one of claims 2-6, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R⁶ is H.
8. The compound of any one of claims 1-7, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R⁴ is halogen, -OR⁷, C₁₋₆alkyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, -C(O)NR⁸R⁹, C₂₋₉heterocycloalkyl, C₆₋₁₀aryl, or C₁₋₉heteroaryl, wherein C₂₋₉heterocycloalkyl, -C₁₋₆alkyl-C₂₋₉heterocycloalkyl, C₆₋₁₀aryl, C₁₋₉heteroaryl are optionally substituted with 1 or 2 R¹⁴.
9. The compound of claim 8, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R⁴ is halogen or R⁴ is C₂₋₉heterocycloalkyl optionally substituted with 1 or 2 R¹⁴.
10. The compound of claim 9, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R⁴ is an unsubstituted C₂₋₉heterocycloalkyl.
11. The compound of any one of claims 1-10, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R⁵ is H, halogen, C₁₋₆alkyl, C₁₋₆haloalkyl, or C₁₋₆haloalkoxy.
12. The compound of any one of claims 1-11, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R² is H.
13. The compound of any one of claims 1-12, or a solvate, hydrate, tautomer, *N*-oxide, stereoisomer, or pharmaceutically acceptable salt thereof, wherein R¹ is -C(O)OR¹⁵ and R¹⁵ is H.
14. A compound selected from:
























or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.


15. A compound selected from:






























16. The compound according to claim 1, wherein the compound is




17. The compound according to claim 1, wherein the compound is




18. The compound according to claim 1, wherein the compound is



19. The compound according to claim 1, wherein the compound is



20. The compound according to claim 1, wherein the compound is



21. A pharmaceutical composition comprising a compound of any one of claims 1-20, or a solvate, hydrate, tautomer, *N*-oxide, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
22. Use of a therapeutically effective amount of a compound of any one of claims 1-20, or a solvate, hydrate, tautomer, *N*-oxide, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating pain in a patient in need thereof.
23. Use of a therapeutically effective amount of a compound of any one of claims 1-20, or a solvate, hydrate, tautomer, *N*-oxide, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating migraine in a patient in need thereof.